# US 2008/0269259 A1 · Regulation of Autophagy and Cell Survival

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269259 A1
- Document ID: US20080269259A1
- Status: Published application
- Kind: A1
- Application number: 11/814,365
- Filed: 2006-01-19
- Published: 2008-10-30
- Earliest claimed: 2005-01-19
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Craig B. Thompson; Julian Lum; Daniel Bauer
- Web page: https://patentgrep.com/patent/US20080269259A1

## CPC

- C12Q 1/26: involving oxidoreductase
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- G01N 33/575: for cancer
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods of treating an individual who has been identified as having glycolysis dependent cancer are disclosed. The methods comprise the step of: administering to such an individual a combination of an anti-cancer composition that renders the cancer incapable of glycolysis and an autophagy inhibitor. Pharmaceutical compositions and kits comprising that renders the cancer incapable of glycolysis and an autophagy inhibit are also disclosed. Methods of treating an individual who has a disease characterized b cell degeneration and cell death due to autophagy are disclosed. The methods comprise administering to the individual a permeable form of a metabolic substrate that can be oxidized in the tricarboxylic acid cycle to produce NADH. Methods for identifying an autophagy inhibitor comprising performing a test assay using an apopto sis-resistant cell are disclosed.

## Claims

### Claim 1

A method of treating an individual who has been identified as having a glycolysis dependent cancer comprising the step of: administering in combination, one or more first anti-cancer compositions and one or more second anti-cancer composition, wherein said first anti-cancer composition is a compound that converts glycolysis dependent cancer to cells incapable of glycolysis, and said second anti-cancer composition is an autophagy inhibitor.

### Claim 2 (depends on 1)

The method of claim 1 wherein the first anti-cancer composition is selected from the group consisting of: Alkylating Agents; Nitrosoureas; Antitumor Antibiotics; Corticosteroid Hormones; Anti-estrogens; Aromatase Inhibitors; Progestins; Anti-androgens; LHRH agonists; Kinase Inhibitors; and Antibody therapies.

### Claim 3 (depends on 1)

The method of claim 1 wherein the first anti-cancer composition is selected from the group consisting of: Alkylating Agents; Corticosteroid Hormones; Anti-estrogens; Aromatase Inhibitors; Kinase Inhibitors; and Antibody therapies.

### Claim 4 (depends on 1)

The method of claim 1 wherein the first anti-cancer composition is selected from the group consisting of: busulfan, cisplatin, carboplatin, chlorambucil, cyclophosphamide, ifosfamide, dacarbazine (DTIC), mechlorethamine (nitrogen mustard), melphalan, carmustine (BCNU), lomustine (CCNU), dactinomycin, daunorubicin, doxorubicin (Adriamycin), idarubicin, mitoxantrone, prednisone, dexamethasone, tamoxifen, fulvestrant, anastrozole, letrozole, megestrol acetate, bicalutamide, flutamide. leuprolide, goserelin, gleevac, Iressa, Tarceva, Herceptin, Avastin, L-asparaginase and tretinoin.

### Claim 5 (depends on 1)

The method of claim 1 wherein the autophagy inhibitor is selected from the group consisting of: chloroquine, 3-methyladenine, hydroxychloroquine, bafilomycin Al, 5-amino-4-imidazole carboxamide riboside, okadaic acid, autophagy-suppressive algal toxins which inhibit protein phosphatases of type 2 A or type 1, analogues of cAMP, and drugs which elevate cAMP levels, adenosine, N6-mercaptopurine riboside, wortmannin, vinblastine, antisense that inhibits expression of proteins essential for inducing autophagy and siRNA that inhibits expression of proteins essential for inducing autophagy.

### Claim 6 (depends on 1)

The method of claim 1 wherein the first anti-cancer composition is administered prior to the second anti-cancer composition.

### Claim 7 (depends on 1)

The method of claim 1 wherein the first anti-cancer composition and the autophagy inhibitor are administered simultaneously.

### Claim 8 (depends on 1)

The method of claim 1 the individual has been identified as having a cancer selected from the group consisting of: Lung, Colon, Breast, Prostate, Pancreas, Lymphoid, Stomach, Rectum, Brain, Melanoma, Ovarian, Testicular and Bone.

### Claim 9 (depends on 1)

The method of claim 1 comprising the step of identifying the patient as having a glycolysis dependent cancer by performing a PETscan prior to administration of the first anti-cancer compound.

### Claim 10 (depends on 1)

The method of claim 1 comprising the step of identifying the patient as having a glycolysis dependent cancer by testing a sample of cancer cells obtained from the individual prior to administration of the first anti-cancer compound for glycolysis activity.

### Claim 11

A pharmaceutical composition or kit comprising one or more first anti-cancer compositions and one or more second anti-cancer compositions, wherein said first anticancer composition is a compound that converts glycolysis dependent cancer to cells incapable of glycolysis, and said second anti-cancer composition is an autophagy inhibitor.

### Claim 12 (depends on 11)

The pharmaceutical composition or kit of claim 11 wherein the first anti-cancer composition is selected from the group consisting of: Alkylating Agents; Nitrosoureas; Antitumor Antibiotics; Corticosteroid Hormones; Anti-estrogens; Aromatase Inhibitors; Progestins; Anti-androgens; LHRH agonists; Kinase Inhibitors; and Antibody therapies.

### Claim 13 (depends on 11)

The pharmaceutical composition or kit of claim 11 wherein the first anti-cancer composition is selected from the group consisting of: Alkylating Agents; Corticosteroid Hormones; Anti-estrogens; Aromatase Inhibitors; Kinase Inhibitors; and Antibody therapies.

### Claim 14 (depends on 11)

The pharmaceutical composition or kit of claim 11 wherein the first anti-cancer composition is selected from the group consisting of: busulfan, cisplatin, carboplatin, chlorambucil, cyclophosphamide, ifosfamide, dacarbazine (DTIC), mechlorethamine (nitrogen mustard), melphalan, carmustine (BCNU), lomustine (CCNU), dactinomycin, daunorubicin, doxorubicin (Adriamycin), idarubicin, mitoxantrone, prednisone, dexamethasone, tamoxifen, fulvestrant, anastrozole, letrozole, megestrol acetate, bicalutamide, flutamide, leuprolide, goserelin, gleevac, Iressa, Tarceva, Herceptin, Avastin, L-asparaginase and tretinoin.

### Claim 15 (depends on 11)

The pharmaceutical composition or kit of claim 11 wherein the autophagy inhibitor is selected from the group consisting of: chloroquine, 3-methyladenine, hydroxychloroquine, bafilomycin Al, 5-amino-4-imidazole carboxamide riboside, okadaic acid, autophagy-suppressive algal toxins which inhibit protein phosphatases of type 2A or type 1, analogues of cAMP, and drugs which elevate cAMP levels, adenosine, N6-mercaptopurine riboside, wortmannin, vinblastine, antisense that inhibits expression of proteins essential for inducing autophagy and siRNA that inhibits expression of proteins essential for inducing autophagy.

### Claim 16

A method of treating an individual who has a disease characterized by cell degeneration and death due to autophagy comprising the step of: administering to the individual a metabolic substrate that can be oxidized in the tricarboxylic acid cycle to produce NADH in a therapeutically effective amount to inhibit cell death by autophagy in cells in the individual.

### Claim 17 (depends on 16)

The method of claim 16 wherein the metabolic substrate is a cell permeable form of pyruvate.

### Claim 18 (depends on 16)

The method of claim 16 wherein the metabolic substrate is methyl pyruvate.

### Claim 19

A method for identifying an autophagy inhibitor comprising performing a test assay comprising:
a) withholding growth factor from a growth factor-dependent, apoptosis-resistant cell to induce autophagy;
b) contacting a test compound with the growth factor-dependent, apoptosis-resistant cell undergoing autophagy; and
c) measuring autophagy, wherein a decrease in autophagy compared to autophagy in a same type of growth factor-dependent, apoptosis-resistant cell undergoing autophagy in the absence of the test compound indicates that the test compound is an autophagy inhibitor.

### Claim 20

A method for identifying an autophagy inhibitor comprising performing a test assay comprising:
a) withholding growth factor from growth factor-dependent, apoptosis-resistant cells to induce autophagy;
b) contacting a test compound with the growth factor-dependent, apoptosis-resistant cells undergoing autophagy; and
c) measuring cell death, wherein a decrease in autophagy of an apoptosis-resistant, growth-factor-deprived cell leads to a loss of cell viability that is not observed when the cells are treated with the same compound in the presence of a growth factor that promotes autophagy-independent cell survival, indicating that the test compound is an inhibitor of autophagy.

### Claim 21 (depends on 19)

The method of claim 19 wherein the apoptosis-resistant cell is an IL-3 dependent cell.

### Claim 22 (depends on 19)

The method of claim 19 wherein said apoptosis-resistant cell is deficient in Bax gene expression and Bak gene expression.

### Claim 23 (depends on 19)

The method of claim 19 wherein said measuring autophagy comprises measuring LC3 localization or LC3 conversion.

### Claim 24 (depends on 19)

The method of claim 19 further comprising performing a negative control assay which comprises contacting an apoptosis-resistant cell with a negative control compound and measuring autophagy.

### Claim 25 (depends on 19)

The method of claim 19 further comprising performing a positive control assay which comprises contacting an apoptosis-resistant cell with a positive control compound and measuring autophagy.

### Claim 26 (depends on 19)

The method of claim 19 further comprising measuring autophagy in an apoptosis-resistant cell in the absence of the test compound.
